(Q37864141)

24 August 2017

1 reference

title

A systematic review of the psychiatric side-effects of efavirenz (English)

1 reference

24 August 2017

1 reference

1 reference

Christopher A Kenedi

1

1 reference

24 August 2017

Harold W Goforth

series ordinal

2

1 reference

24 August 2017

publication date

1 November 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1803-1818

1 reference

https://scigraph.springernature.com/pub.10.1007/s10461-011-9939-5

24 August 2017

exact match

0 references

cites work

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Once‐a‐Day Highly Active Antiretroviral Therapy: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Recurrence of post-traumatic stress disorder and antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

A manic episode associated with efavirenz therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Management of sudden psychiatric disorders related to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Factors associated with efavirenz discontinuation in a large community-based sample of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Association between efavirenz and selected psychiatric and neurological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Use of amitriptyline to offset sleep disturbances caused by efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz-induced psychosis leading to involuntary detention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Neuropsychiatric effects of efavirenz: delayed onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Efavirenz-induced catatonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

Manic syndrome associated with efavirenz overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10461-011-9939-5

10.1007/S10461-011-9939-5

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference